The anti-diabetic drug Metformin (MET) has been shown to reduce the incidence of prostate cancer, while the anti-epileptic drug Valproic Acid (VPA) has also been shown to have an anti-tumor effect. Here we aimed to determine if the combination of MET and VPA would induce at least an additive anti-tumour effect in prostate cancer due to their different mechanisms of action, and whether common mutations in prostate cancer (e.g. TP53 and AR genes) would affect the response.
- androgen receptor signaling
- personalized prostate cancer treatment
- valproic acid
- Combination of metformin and valproic acid